Choy, H., Nabid, A., Stea, B., Scott, C., Roa, W., Kleinberg, L., Ayoub, J., Smith, C., Souhami, L., Hamburg, S., Spanos, W., Kreisman, H., Boyd, A.P., Cagnoni, P.J, Curran, W.J. Phase II multicenter study of induction chemotherapy followed by concurrent Efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small cell lung cancer. J Clin Oncol. 23, 5918-28, 2005.
Suh, J., Stea, B., Nabid, A., Fortin, A., Mercier, J.P., Senzer, N., Chang, E., Boyd, A.P., Cagnoni, P.J., Shaw, E. Results from a phase III study evaluating Efaproxiral as an adjunct to whole brain radiation therapy for the treatment of patients with brain metastases. J Clin Oncol. 24(1):106-14, 2006.
Gabayan, A.J., Green, S.B., Sanan, A., Jenrette, J., Schultz, C., Papagikos, M., Tatter, S.P., Patel, A., Amin, A., Tonnesen, G.L., Lusting, R., Bastin, K.T., Watson, G., Burri, S., Stea, B. GliaSite radiotherapy system for treatment of recurrent gliomas. Neurosurgery. 58:701-709, 2006.
Stea, B., Suh, J.H., Boyd, A.P., Cagnoni, P.J., Shaw, E. Whole brain radiation therapy with or without Efaproxiral for the treatment of brain metastases: determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys. 64(4):1023-30, 2006.
Welsh, J., Gabayan, A., Green, S.B., Lustig, R., Burri, S., Kwong, E., Stea, B. GilaSite Radiotherapy Boost as part of the initial treatment of Glioblastoma Multiforme: a retrospective multi-institutional pilot study. Inter J Rad Oncol Biol Phys. 68(1), 159-165, 2007.
Pawar, S., Dougherty, S., Pennington, M.E., Demetriou, M.C., Stea, B., Dorr, R.T., Cress, A.E. |*alpha*|6 Integrin Cleavage: Sensitizing Human Prostate Cancer to Ionizing Radiation. Int J Radiat. Biol. 83(11):761-767, 2007.
Persky, D., Unger, J., Spier, C.M., Stea, B., Maloney, D.G., LeBlanc, M., Rimsza, L.M., Fisher, R.I., Miller, T.P. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. J Clin Oncol. 10:26(14):2258-63, 2008.
Watchman, C., and Stea, B. Patient positioning using implanted gold markers with the Novalis Body System in the Thoracic Spine. Neurosurgery. 62, A62-A68, 2008.
Chino, K., Grace, A., Silvain, D. Stea, B. Outpatient brachytherapy for patients with brain tumors using the GliaSite RTS system. Med Phys 2008 Jul: 35(7):3383-8.
Welsh J, Mahadevan D, Bearss D, Cooke L, Dougherty G, Stea B; A c-Met receptor Thyrosine Kinase Inhibitor Radiosensitizes Glioblastoma. Radiation Oncology 4:69, 2009
Badruddoja MA, Elquza E, Welsh J, Cooke L, Sana A, Stea B, Mahadevan, D; The development of PDGF Receptor Inhibitors for the Treatment of Gliomas: A Review. Lett in Drug Design Discovery. 2010; 7(4): 290-299
Daley SK, Michael J Bernas MJ, Stea B, Bracamonte E, McKenna M, Stejskal A, HirlemanE, and Marlys H Witte.Radioprotection from radiation induced lymphedema without tumor protection. Lymphology 43 (2); 48-58, 2010
Stea B, Hazard JL, Gonzalez JV and Hamilton JR. The Role of Radiation Therapy in the Control of Locoregional and Metastatic Cancer J. Surg Oncol. 2011 May 1; 103 (6):627-638. Review
Stea B and Gordon J. Clinically Relevant Biomarkers in Targeted Radiotherapy. Clinical and Experimental Metastases (in press, 2012)
Welsh, JW, Komaki R, Amini A, Munsell M, Unger W, Allen PK, Chang JY, Wefel J, McGovern S, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, and Stea B; Phase II Trial of Erlotinib plus Concurrent Whole-Brain Radiation Therapy for Patients with Brain Metastases from Non-Small Cell Lung Cancer. In press 2012 JCO